ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2821

Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?

Chi Chiu Mok1, Ling Yin Ho2, Chi Hung To3 and Kar Li Chan1, 1Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 2Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong, 3Medicine, Pok Oi Hospital, Hong Kong, Hong Kong

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cardiovascular disease and uric acid, Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  To evaluate whether hyperuricemia is independently associated with cardiovascular events in a cross-sectional study of Chinese patients with SLE.

Methods:  Consecutive patients who fulfilled ≥4 ACR criteria for SLE were recruited from our rheumatology clinics. Fasting blood was taken for serum urate level, along with other atherosclerosis risk factors that included glucose and lipid profile (total, LDL, HDL cholesterol and triglyceride). Patients were assessed for body weight, body height, waist circumference and the presence of the metabolic syndrome (MetS) as defined by the updated joint consensus criteria, using the Asian criteria for central obesity. The 4-variable estimated glomerular filtration rate (eGFR) was also calculated. Patients were stratified according to different serum urate levels: <0.35mmol/L, 0.35-0.48mmol/L, 0.48-0.60mmol/L and >0.60mmol/L. Comparison of the prevalence of vascular risk factors, the MetS and arterial thrombotic events (acute coronary syndrome, stroke, peripheral vascular event) was made among patients with different levels of serum urate. Cox regression models were established to study whether hyperuricemia was independently associated with arterial events with adjustment of demographic variables, eGFR, vascular risk factors and the antiphospholipid (aPL) antibodies.

Results: 485 SLE patients were studied (93% women; mean age 46.2±14 years); 259 (53%) had renal involvement and 73 (15%) had chronic kidney disease stage 3 or more. Hyperuricemia (urate >0.35mmol/L) was present in 185 (38%) patients. The number of patients who had serum urate levels of 0.35-0.48, 0.48-0.60 and >0.60mmmol/L was 131 (27%), 40 (8.7%) and 14 (2.9%), respectively. Patients with hyperuricemia, compared with those without, were more likely to be men (14% vs 3%; p<0.001), have renal disease (72% vs 42%; p<0.001), hypertension (34% vs 15%; p<0.001), lower eGFR (73.4±34 vs 101±27; p<0.001) but longer SLE duration (14.3±8.7 vs 12.1±7.4 years; p=0.006). The LDL-cholesterol level (3.34±1.37 vs 2.89±1.51mmol/L; p=0.001), triglyceride level (1.62±0.77 vs 1.29±0.78mmol/L; p<0.001), body mass index (BMI) (23.2±4.5 vs 22.3±3.8kg/m2; p=0.04) and occurrence of the MetS (22% vs 12%; p=0.007) were significantly higher in patients with hyperuricemia. On the contrary, patients with the MetS had significantly higher serum urate levels than those without (0.38±0.11 vs 0.34±0.13mmol/L; p=0.007). Over an observation of 12.9±8.0 years, 50 acute arterial events (17 acute coronary syndrome; 24 stroke, 7 peripheral vascular event and 2 retinal artery thrombosis) developed in 47 patients. The cumulative risk of arterial thrombosis was 5.2% and 6.4% in 10 and 15 years, respectively. Acute coronary events were significantly more common in patients with hyperuricemia than those without (7.6% vs 1.0%; p=0.001). Cox regression analysis revealed that HDL<1.0mmol/L (HR 3.44[1.62-7.27]; p=0.001], lupus anticoagulant (HR 3.84[1.92-7.65]; p<0.001) and age of SLE onset (1.03[1.004-1.05] per year; p=0.02) were independently associated with arterial thrombosis. In separate regression models, elevated urate levels (>0.35, >0.48 or >0.60mmol/L) were not significantly associated with arterial events after adjustment for age, sex, eGFR, smoking, LDL-cholesterol, HDL-cholesterol, triglyceride, BMI, diabetes mellitus, hypertension and the antiphospholipid antibodies.

Conclusion: Hyperuricemia was associated with renal dysfunction, obesity, hypertension and dyslipidemia in patients with SLE. Moreover, elevated serum urate level was also associated with the occurrence of the MetS and acute coronary events. However, in multivariate regression models, hyperuricemia was not an independent risk factor for acute coronary or any arterial events after adjustment for confounding factors.


Disclosure: C. C. Mok, None; L. Y. Ho, None; C. H. To, None; K. L. Chan, None.

To cite this abstract in AMA style:

Mok CC, Ho LY, To CH, Chan KL. Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/is-hyperuricemia-an-independent-risk-factor-for-arterial-thrombosis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-hyperuricemia-an-independent-risk-factor-for-arterial-thrombosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology